Editorials

Screening for MCAD deficiency in newborns

BMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b971 (Published 26 March 2009) Cite this as: BMJ 2009;338:b971
  1. Clodagh Loughrey, consultant chemical pathologist1,
  2. Michael J Bennett, director, metabolic disease laboratory 2
  1. 1Belfast Health and Social Care Trust, Belfast City Hospital, Belfast BT9 7AB
  2. 2Children’s Hospital of Philadelphia, Department of Pathology and Laboratory Medicine, Philadelphia, PA 19104-4399, USA
  1. clodagh.loughrey1{at}belfasttrust.hscni.net

    Saves lives and is now offered to every baby in England and Northern Ireland

    This month sees the expansion of newborn screening in England and Northern Ireland to include screening for medium chain acylcoenzyme A dehydrogenase (MCAD) deficiency within the entire newborn population. MCAD deficiency is the most common inherited disorder of mitochondrial fatty acid oxidation in people from northern Europe. This autosomal recessive metabolic disease affects about one in 10 000 people in the United Kingdom,1 and it has a common mutation (985A>G) with a carrier rate of around one in 65.2 Homozygosity for this mutation has not been found in black or Asian ethnic groups that have been screened in England, which suggests that MCAD deficiency caused by the 985A>G mutation is a disease of white ethnic origin.2

    Individuals with undiagnosed MCAD deficiency typically present clinically with failure of fatty acid oxidation after fasting and an inability to generate energy during periods of increased energy demand. This may manifest as symptomatic hypoglycaemia through hepatic encephalopathy (similar to that seen in Reye’s syndrome) to sudden unexpected infant death, which may …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe